Author of

• 12441

  +

  P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12459

    +

    P3.06-019 - MDM2 309T>G polymorphism and risk of lung cancer in a Japanese population (ID 1769)

    09:30 - 09:30  |  Author(s): Y. Enokida
    • Abstract

    Background
    The MDM2 protein plays an important role in regulating cell proliferation and apoptosis by interaction with multiple proteins including p53 and Rb. c.309 (rs2279744) polymorphism (T>G) in the MDM2 promoter has been shown to result in higher levels of MDM2 RNA and protein. In order to evaluate the association of the MDM2 309T>G polymorphism and lung cancer risk, we carried out a case-control study in a Japanese population.

    Methods
    The MDM2 genotypes were determined in 469 lung cancer patients and in 682 healthy control subjects using Smart Amplification Process (SmartAmp). Statistical adjustment was made for sex and age.

    Results
    The distribution of the MDM2 309T>G genotypes was not significantly different between control and overall lung cancer cases. Subgroup analysis of KRAS G to T transversion adenocarcinoma indicated that G/G genotype of SNP309 may be associated with lung cancer carcinogenesis (adjusted OR = 2.42 95% C.I. = 1.01-5.82 p = 0.05) compared to T/T + T/G genotypes. G/G genotype has lower-level exposure to cigarette smoke than T/T + T/G genotypes (p=0.03) among squamous cell lung cancer patients. There was however no effect of either polymorphism on age at diagnosis of lung cancer or on overall survival.

    Conclusion
    Our results indicate that the MDM2 309T>G polymorphism is not significantly associated with lung carcinogenesis but may be associated with smoking related cancer of the lung.